BAP1 and Miyoshi myopathy: Conversely, they exert a weaker inhibitory effect in MM cells that also harbor BAP1 mutations [112]; thus, the effectiveness of statin treatments in MM cells appears to vary dependent upon the cellular genetic/epigenetic background.